Scientists unravel
Andhra Pradesh ~ India ~ International ~ City ~ Entertainment ~ Business ~ Sports ~ Technology ~ Health ~ Features
Breast Cancer ~ Swine Flu ~ Lung Cancer ~ Heart attack ~ Pregnancy ~ All Health Topics
Home / Health News / 2009 / July 2009 / July 21, 2009
Scientists unravel why placebos work as effectively for some people as real ones
RSS / Print / Comments

Health News

Waist size, not BMI can foretell cardiovascular risk in children
A new study by researchers at the University of Georgia, the Menzies Research Institute in Hobart, Australia and the Murdoch Childrens Research Institute in Melbourne, Australia has found that waist circumference is a better indicator of a childs risk for cardiovascular disease and diabetes later in life, as compared to BMI. ANI

Internal body temperature regulates body clock
Fluctuations in internal body temperature regulate the bodys circadian rhythm, the 24-hour cycle that controls metabolism, sleep and other bodily functions, revealed UT Southwestern Medical Center researchers. ANI

Egyptian mummies discovery indicates 'cancer is man-made'
A study of ancient remains has found that cancer is a man-made disease fuelled by pollution and changes to diet and lifestyle. ANI

Scientists unravel why placebos work as effectively for some people as real ones

Researchers at the University of California-Los Angeles (UCLA) have come up with an explanation for why placebos-sham pills often used for clinical studies-work nearly as well for some people as real medication.


Washington, July 21 : Researchers at the University of California-Los Angeles (UCLA) have come up with an explanation for why placebos-sham pills often used for clinical studies-work nearly as well for some people as real medication.

Dr. Andrew Leuchter, a professor of psychiatry at the UCLA Semel Institute for Neuroscience and Human Behavior, has found that in people suffering from major depressive disorder (MDD), genes that influence the brain's reward pathways may modulate the response to placebos.

Writing about their work in the the Journal of Clinical Psychopharmacology, the researchers point out that placebos are thought to act by stimulating the brain's central reward pathways by releasing a class of neurotransmitters called monoamines, specifically dopamine and norepinephrine.

These are the brain chemicals that make us "feel good", they say in the report.

As the chemical signaling done by monoamines is under strong genetic control, the scientists reasoned that common genetic variations between individuals - called genetic polymorphisms - could influence the placebo response.

During the study, the research team took blood samples from 84 people diagnosed with MDD. They gave 32 persons medication, and 52 a placebo.

The researchers then looked at the polymorphisms in genes that coded for two enzymes that regulate monoamine levels: catechol-O-methyltransferase (COMT) and monoamine oxidase A (MAO-A).

They observed that the people who had the highest enzyme activity within the MAO-A polymorphism had a significantly lower placebo response than those with other genotypes.

With respect to COMT, according to the researchers, those with lower enzyme activity within this polymorphism had a lower placebo response.

"Our findings suggest that patients with MDD who have specific MAO-A and COMT genotypes may be biologically advantaged or disadvantaged in mounting a placebo response, because of the activity of these two enzymes," said Leuchter, who directs the Laboratory of Brain, Behavior and Pharmacology at the UCLA Semel Institute.

"To our knowledge, this is the first study to examine the association between MAO-A and COMT polymorphisms and a response to placebo in people who suffer from major depressive disorder," he said.

Leuchter concedes that this is not the sole explanation for a response to a placebo, which is likely to be caused by many factors, both biological and psychosocial.

"But the data suggests that individual differences in response to placebo are significantly influenced by individual genotypes," he said.

He believes that including the influence of genotype in the design of clinical trials could facilitate more powerful testing of future treatments.

ANI

Link to this page

Suggested pages for your additional reading
AndhraNews.net on Facebook






© 2000-2017 AndhraNews.net. All Rights Reserved and are of their respective owners.
Disclaimer, Terms of Service & Privacy Policy | Contact Us